These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3102718)

  • 1. A pharmacodynamic model for the activity of antibiotics against microorganisms under nonsaturable conditions.
    Zhi J; Nightingale CH; Quintiliani R
    J Pharm Sci; 1986 Nov; 75(11):1063-7. PubMed ID: 3102718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Investigations on antibacterial activity of apalcillin].
    Stille W; Helm E; Mielenz H
    Arzneimittelforschung; 1982; 32(9):1128-30. PubMed ID: 6816250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of in vitro critical inhibitory concentration, a novel approach to predict in vivo synergistic bactericidal effect of combined amikacin and piperacillin against Pseudomonas aeruginosa in a systemic rat infection model.
    Chan E; Zhou S; Srikumar S; Duan W
    Pharm Res; 2006 Apr; 23(4):729-41. PubMed ID: 16554956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due to Pseudomonas aeruginosa.
    Zhi JG; Nightingale CH; Quintiliani R
    J Pharmacokinet Biopharm; 1988 Aug; 16(4):355-75. PubMed ID: 3193364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The kinetics of bacterial killing by fluctuating concentrations of antibiotics].
    Guggenbichler JP; Allerberger F; Bonatti H; Semenitz E; Dierich MP
    Wien Klin Wochenschr; 1989 Mar; 101(7):224-9. PubMed ID: 2652890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coli.
    Bergen PJ; Bulitta JB; Sime FB; Lipman J; McGregor MJ; Millen N; Paterson DL; Kirkpatrick CMJ; Roberts JA; Landersdorfer CB
    Diagn Microbiol Infect Dis; 2018 May; 91(1):69-76. PubMed ID: 29395712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of physiologic variations in temperature on the rate of antibiotic-induced bacterial killing.
    Mackowiak PA; Ruderman AE; Martin RM; Many WJ; Smith JW; Luby JP
    Am J Clin Pathol; 1981 Jul; 76(1):57-62. PubMed ID: 6789670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum bactericidal activity of piperacillin/tazobactam against Staphylococcus aureus, piperacillin-susceptible and piperacillin-resistant Escherichia coli and Pseudomonas aeruginosa.
    Lemmen SW; Zolldann D; Klik S; Lütticken R; Kümmerer K; Häfner H
    Chemotherapy; 2004 Apr; 50(1):27-30. PubMed ID: 15084802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vanillin selectively modulates the action of antibiotics against resistant bacteria.
    Bezerra CF; Camilo CJ; do Nascimento Silva MK; de Freitas TS; Ribeiro-Filho J; Coutinho HDM
    Microb Pathog; 2017 Dec; 113():265-268. PubMed ID: 29107747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic modeling of bacterial kinetics: beta-lactam antibiotics against Escherichia coli.
    Li RC; Nix DE; Schentag JJ
    J Pharm Sci; 1994 Jul; 83(7):970-5. PubMed ID: 7965677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of different renal function on antibacterial effects of piperacillin against Pseudomonas aeruginosa evaluated via the hollow-fibre infection model and mechanism-based modelling.
    Bergen PJ; Bulitta JB; Kirkpatrick CM; Rogers KE; McGregor MJ; Wallis SC; Paterson DL; Lipman J; Roberts JA; Landersdorfer CB
    J Antimicrob Chemother; 2016 Sep; 71(9):2509-20. PubMed ID: 27231278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect on growth curve patterns of brief exposure of bacteria to different concentrations of beta-lactam antibiotics.
    Yourassowsky E; Van der Linden MP; Lismont MJ; Crokaert F; Glupczynski Y
    J Antimicrob Chemother; 1985 Jan; 15 Suppl A():27-36. PubMed ID: 3920184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibacterial kinetics of ampicillin against Escherichia coli under simulated in vivo conditions.
    Fuglesang JE; Bergan T
    Infection; 1982 Jan; 10(1):31-4. PubMed ID: 7040252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic modeling of the antibiotic effect of piperacillin in vitro.
    Nolting A; Dalla Costa T; Rand KH; Derendorf H
    Pharm Res; 1996 Jan; 13(1):91-6. PubMed ID: 8668686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PK-PD modeling of β-lactam antibiotics: in vitro or in vivo models?
    de Araujo BV; Diniz A; Palma EC; Buffé C; Dalla Costa T
    J Antibiot (Tokyo); 2011 Jun; 64(6):439-46. PubMed ID: 21505469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study of sensitivity of clinical strains of microorganisms to ampicillin and other broad spectrum antibiotics].
    Chavdarova VB; Petrova MA; Navashin SM
    Antibiotiki; 1969 Feb; 14(2):151-4. PubMed ID: 4976747
    [No Abstract]   [Full Text] [Related]  

  • 17. A mathematical model-based analysis of the time-kill kinetics of ceftazidime/avibactam against Pseudomonas aeruginosa.
    Sy SKB; Zhuang L; Xia H; Beaudoin ME; Schuck VJ; Nichols WW; Derendorf H
    J Antimicrob Chemother; 2018 May; 73(5):1295-1304. PubMed ID: 29415212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New in vitro model to study the effect of human simulated antibiotic concentrations on bacterial biofilms.
    Haagensen JA; Verotta D; Huang L; Spormann A; Yang K
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4074-81. PubMed ID: 25918138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Trends in antimicrobial resistance of Pseudomonas aeruginosa, Escherichia coli and Bacteroides fragilis (1997-2001)].
    García-Rodríguez JA; Casal M; Rodríguez F;
    Rev Esp Quimioter; 2003 Dec; 16(4):421-7. PubMed ID: 14961136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.
    Yadav R; Rogers KE; Bergen PJ; Bulitta JB; Kirkpatrick CMJ; Wallis SC; Paterson DL; Nation RL; Lipman J; Roberts JA; Landersdorfer CB
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.